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ةصلاخلا 
   : ثحبلا ةيفلخٍٛطجنا  دبٓجأ ششؤي ٌأ شسٚلأا ٙػبجقَلاا  خٛنٕطنا فبٛنلأن (LVMESS  )لايبػ شجزؼٚ بٛسبسأ  ىٛٛقر ٙف شسٚلأا ٍٛطجنا ءادأ .ميإػ كنبُْ 
خٛسٛئس ٗهػ شثؤر LVMESS بُٓي، كًس ساذج  ىجح ٔ شسٚلأا ٍٛطجنا ٍٛطجنا ٍي لاك ٙف بْدٕجٔ ٍكًًنا ٍي ٙزنا ٍٛطجنا ٍٕٚكرٔ خًُسنا ٔ عشي 
٘شكسنا َٙبثنا عُٕنا  .رذجٕ حشٛثك شٚسبقر ذكؤر  ميبػ شٛثأر ًُٕنا ٘زنا ّجشٚ ٍٛنٕسَلأا (IGF -1 )ٗهػ حدبٚص ششؤي خهزك ٍٛطجنا شسٚلأا  (LVMI )  كنزكٔ،
ٗهػ دبٕٚزسئ A1C . 
فذهلا : فبشكزسلا بي ارإ ٌبك ؽبجرسلاا ىئبقنا ٍٛث LVMESS ٔ IGF- 1 ٙف بيصلاجنا دار ُٕ٘ؼي ٖضغي ، ٙف داشفلأا  خطسٕزًنا خٚشًؼنا خئفنا ٘ر ٔ سبجك 
ٍٚزنا ٍسنا ٌَٕبؼٚ ٍي خًُسنا خؽشفًنا غي ٔأ ٌٔذث ٘شكسنا ءاذن َٙبثنا عُٕنا. 
 ةيدهىملا: ٙف ِزْ خساسذنا فششلأا فجُنا خظفبحي ٙف حٕزفًنا تهقنا ضكشي ٙف ذٚشجأ ٙزنا خٛؼطقًنا ضحف ىر ٍي فنأزر ّػًٕجي 145 بكسبشي .  ذٚشجأ
ءبَذجنا خَسبقي خطسٕزًنا خٚشًؼنا خئفهن ٔ سبجك ٍسنا  غي سفَ خئفنا خٚشًؼنا ٔأ غي  صبخشلأن   ٌٔذث٘شكسنا ءاذن َٙبثنا عُٕنا  .ذًرٔ خَسبقي LVMESS ٔ 
IGF- 1 ٍٛث ؛ دبػبًجنا ذقٔ ىر مٛهحر دبفلازخلاا واذخزسبث دبػًٕجًنا ٍٛث حدشفًنا سبجزخلاا ٙطخنا ٔ سبجزخا ؽبجرسلاا .ةشػأٔ ٍػ دبَبٛجنا بًك ُٙؼٚ  ±
SD، واذخزسبث SPSS ٙف ساذطلإا 18 . 
حئبتىلا : دشٓظأ ىٛقنا عبفخَا  LVMESS خظٕحهي حسٕظث ٙف ٗػشي . ٘شكسنا ذَبك دبٕٚزسي ضٛكشر IGF- 1 مقأ ٙف ٗػشي ٍٚزنا ٘شكسنا ٌَٕبؼٚ 
ٍي خًُسنا ٍُٛسًنا ٔ خؽشفًنا   حشٛجك خُٕٚؼي خجسذث(ص  =0.462 ، P = 0.04 ) خقلاػ كنبُْ.ٍٛث  خٛجهس IGF- 1 ٔ  LVMESS  ٙف ءبَذجنا ءبحطلأا 
. ٘شكسنا ءاذث ٍٛثبظًنا ءبَذجنا شٛغ ٍسنا سبجكٔ  
جبتىتسلاا : خقلاػ شٛغ خٛطخ ضٛكشر دبٕٚزسي ٍٛث IGF- 1 ٔ LVMESS  لٕظحنا ىر بٓٛهػ  .ٍكًٚ عاشزفلاا َّأ تجسث ّزقلاػ خٛجهسنا غي LVMESS  
ٙف سبجك ٍسنا شٛغ ءبَذجنا ٍٛثبظًنا ءاذث  ٘شكسنا.  
:تبيصىتلا دبٕٚزسي واذخزسا ٍكًًنا ٍي IGF- 1 ٌٕكزن خثبثًث ششؤي فؼؼن خفٛظٔ  شسٚلأا ٍٛطجناخٛػبجقَلاا .خفبػلإبث ٗنإ  ٍكًًنا ٍي َّاءبقنإ غؼث 
ءٕؼنا ٗهػ خقلاؼنا IGF -1- LVMESS ، ذُػ شظُنا ٙف  جلاؼناواذخزسبث IGF- 1 ٙف ٍُٛسًهن فٔشظ خُٛؼي.  بًجح شجكا دبُٛػ واذخزسبث ٙطَٕ كنزك
 سٕحث ٙفٖشخأ  حسٕكزًنا خقلاؼنا خساسذنبفَآ. 
Abstract:  
Background: Left ventricular meridional end systolic stress (LVMESS) is a quantitative determinant  index of LV 
afterload which is an essential determinant of LV performance.  The key factors influencing LVMSS, notably 
ventricular wall thickness, chamber  size and configuration  are shown to be  altered  by both obesity and type2 diabetes 
mellitus (T2DM). There exist reports implicating high  free insulin-like growth factor 1 (IGF-1) but not growth 
hormone (GH) levels, with increased left ventricular mass index (LVMI), abnormal LV geometric remodelling, and 
A1c levels.                                                                                                                                                 
Objective: to explore whether a meaningful link exists between LVMESS and free IGF-1 plasma levels, in  obese 
middle-aged and elderly individuals with or without T2DM.                  
Subjects and methods:  In this cross sectional study, a total of 145 participants Involved. Middle aged and elderly 
obese individuals with or without  T2 DM were matched with healthy lean subjects of the  same age group, with or 
without T2 DM. LVMESS and IGF-1 levels were compared between groups; group differences were analyzed using 
unpaired t test and linear correlation test. Data were expressed as the mean ± S.D, using SPSS version 18).                                                                                   
Results: LVMESS values showed significant decrease in diabetic patients compared to control in both middle and old 
aged subjects. IGF-1, concentration levels were lower in the elderly obese diabetics compared to control, with 
significant (r=0.462; p= 0.04) negative correlation with LVMESS in  healthy obese old aged, and   a negative but non-
significant correlation with LVMESS in lean old aged with or without diabetics. 
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Conclusion: Nonlinear correlation of IGF-1 levels with LVMESS obtained. It could   be hypothesized that because of  
its negative significant correlation with LVMESS in the elderly non diabetic obese, IGF-1 free level could be utilized to 
serve as a predictor of impaired LV systolic function in these subjects.  In addition the results could shed some light on 
IGF-1- LVMESS relationship, when considering IGF-1 therapy in certain conditions.  
Recommendation: It is suggested that using IGF-1 plasma levels in the elderly with or without T2DM could aid as 
predictor for LV  global systolic dysfunction .However, larger sample size are to be considered. 
Keywords: IGF- 1, left ventricular meridional end systolic stress, obesity, Type 2 Diabetes Mellitus. 
 
INTRODUCTION:  
Because of the biased validity of  LV systolic function assessment by ejection fraction (EF) 
index, two other types of load independent estimates have been proposed for this purpose: the 
meridional  LV  wall stress which reflects  the function  of the longitudinal endocardial and 
epicardial fibers of the LV wall, has been used as  an indirect measure  of LV after load. The 
circumferential LV wall stress which is in line with the direction of the mid wall circumferential 
fibers and  has been used as a measure of myocardial contractility 
(1,2)
 . The concept of after load 
literally means the stress encountered by LV myofibrils as they contract against the end-diastolic 
volume/ intra -ventricular pressure. obese individuals with or without diabetes tend to develop left 
ventricular (LV) structural changes in response to the operating overload: volume overload causing 
chamber dilation in proportion to mass (eccentric hypertrophy), and pressure overload   producing  
increased LV mass out proportion to volume (concentric hypertrophy).  These patterns of 
hypertrophy are independent of arterial pressure and age 
(3, 4).
.                                                                                                            
Diabetic and hypertensive subjects have a higher likelihood to develop, impaired diastolic 
function, in addition to decreased afterload measured by meridional end-systolic stress, as  
compared with lean individual 
(5,6)
. Indeed, DM exclusively, can elicit changes in cardiac structure 
and function  which are independent of associated ischemic heart disease or hypertension or 
increased BMI 
(7,8)  
                                                                                                                                 
Mounting evidence indicate growth hormone (GH)/ Insulin growth factor 1(IGF-1) axis  also 
known to contribute to LV structural and functional modulations: Circulating IGF-1 is synthesized 
primarily by the liver under the control of growth hormone (GH) 
(9)
. However, IGF-1 can be 
synthesized by many other organs, including heart, and can act as an autocrine or a paracrine factor 
(10)
. IGF-1 circulates bound to protein carriers (IGFBPs), which serve not only to transport IGF-1 in 
the circulation but also to prolong its half-life, modulate its tissue specificity and strengthen or 
neutralize its biological actions 
(11)
 
As growth factors, both GH andIGF-1 modulate myocyte growth and hypertrophy in the 
developing heart.  IGF-1 has been demonstrated to induce nitric oxide (NO) production in vitro and 
has vasodilatory properties consistent with an NO-mediated effect in vivo that induces cellular 
proliferation and differentiation.  In addition, it exerts both inotropic and growth effects that can 
influence LV geometry (
12,13)
. However, until the time of preparation of this manuscript, studies on 
the impact of alteration of IGF-1 axis on meridional LV wall stress in obesity and obesity- related 
T2DM, are lacking. 
Objectives 
This study defined whether a relationship exsist between LVMESS and free LGF-1 plasma levels in 
obese middle age and elderly individuals with or without T2DM.  
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METHODOLOGY 
A total of 145 participants were recruited from  Al Najaf cardiac center,  after having their 
verbal and written consent and approval from the ethical committee at  our hospital. The subjects 
were classified into 3 groups.  Group 1 subjects served as a control and were subdivided into group 
1A, comprised healthy lean middle-aged (n=18,  mean age 53±4.3yrs, and  BMI 23±2.8 kg/ m
2
), 
and healthy lean old aged individuals ( n=15; mean age 64±3.2;  BMI 24±1.7 kg/ m
2
). Group 1B, 
involved diabetic lean middle-aged (n= 14; mean age, 57±3.8yrs; BMI 22.4±3.23 kg/ m
2
), and 
diabetic lean old-aged (n= 21; mean age, 60±3.3yrs;  BMI, 21.5±4.3 kg/ m
2
). Group 2 involved 
healthy obese middle-aged (n=17; mean age, 48±36 yrs; BM, I34.5±7.6 kg/m
2
), and old aged obese 
subjects( n=29; mean age 65±5.3 yrs; BMI, 32.5±4.3 kg/m
2
 ), and group 4, involved diabetic obese 
middle-aged (n=15; mean age,57±3.8yrs; BMI 30.4±6.23 kg/m
2
), and  diabetic old-aged subjects 
(n=16; mean age, 64±2.8yrs; BMI, 32.5±4.3 kg/ m
2
). The inclusion criteria in this study were  the 
exclusion of hypertension by an extensive examination, absence of cardiac or other chronic 
diseases, no metabolic disorders or pregnancy among women and good-quality echocardiograms at 
baseline evaluation. No subject was a competitive athletics. History should be taken to rule out 
medication intake, smoking habit, number of cigarette, duration of diabetes regarding diabetics' 
patients. The volunteers and patients had their body weight measured by using weight device with 
subject wearing no shoes. Height was measured by using a tape measure. Body mass index (BMI) 
was calculated as weight divided by height (kg/ m
2
) according to the universal formula
(14).
                                                                                               
Left ventricular end systolic stress (LVMESS) can be calculated from the LV peak pressure 
P, the myocardial area “Am”, and the LV cavity area “Ac” in the short-axis view at the papillary 
muscle level done at end-systole.                                                                                                                                    
LVESMS = 1.33P (Ac/Am) x 103 dyne/cm³. (Reported normal values for LVESMS between 
65 to 73  dynes/ cm³ 
(15)
.  
Echocardiography 
 All patients had a resting echocardiography with commercially available tranthoracic 
echocardiography (Philips HDI 22100/ IE33, Bothell, A 98021-8431 made in USA) in cardiac 
center in AL Sader Teaching hospital, with the patients in partial left decubitus position. Two-
dimensional and M-mode echocardiography are utilized to assess end-systolic meridional stress and 
its relationship to left ventricular cavity length, end-systolic circumferential stress and its 
relationship with left ventricular internal diameter. 
 
 
 
 
                                     
                                        A                                                            
Fig 1 (A) Short-axis view of the left ventricle, at end-systole. (B) Apical four chamber view to 
assess LV diastolic length.                                                                                          
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Laboratory assay 
Fasting blood samples for at least 12 hrs were collected according to a standardized protocol 
from each subject; 6 ml of blood was drawn. Filled syringes were kept at 5-10 c, protected from 
light, and transferred to a local laboratory for centrifugation.  3 serum tubes for each sample were 
collected and freeze at -20°c until the time of assay.  
Human IGF-1 was used (IGF-1 600 ELISA was manufactured by Demeditec Diagnostic 
GmbH.Lise-Meiter-StraBe2.D-24145 Kiel, (Germany). ELISA technique for direct quantitative 
determination of human IGF-1 levels 
 
Statistical Analyses 
Data were analyzed as per age groups group I (20-40 yrs), group II (40-60 yrs), group III (60-
80yrs); each age group was further divided into 3 groups according their BMI into lean those has 
BMI < 25 kg/m2; overweight, those with BMI ranging from 24.9-29.9 kg/m2 and obese those with 
BMI > 30 kg/m2 .The results were expressed as mean and standard deviations. Analysis of variance 
(ANOVA) as well as correlation regression test and independent T test (using SPSS version 18) 
were applied to compare the study groups. Probability P value of < 0.05 was considered statistically 
significant (α≤0.05)                                                                                                                                 
RESULTS 
Table 1: Subjects' profile of echocardiographic and IGF-1 levels in healthy individuals and 
diabetics, of age ranging between 40-60 yrs (n=64) 
Groups 
 
LVESMS 
dyne/cm 
LVMI LVM IGF-1ng/ml 
Lean 
Diabetic 
n=14 
49.88±22.82 174.13±52.57 182.03±49.15 44.67±19.77 
Healthy 
n=18 
66.27±25.53 204.20±38.37 219.04±69.5 49.89±23.18 
   P value  
 
0.084 0.05       0.40 0.561 
Obese 
Diabetic 
n= 15 
53.13±19.92 157.21±55.11 212.2±52.27 47.50±23.18 
Healthy 
n=17 
62.52±11.93 200.42±100.16 245.5±45.82 48.05±35.78 
   P value 0.05* 0.141 0.12 0.959 
 
Table 1 shows that, in lean middle- aged individuals, LVMESS did  not show a statically 
significant difference between diabetics and healthy individuals. Whereas in obese middle- aged 
individuals, a significant decrease in LVMESS in diabetics was observed compared to healthy 
individuals. The LVMI showed a decrease in obese individuals in both diabetics and healthy 
subjects, but this decrease did not reach  a significant level. LVM showed a significant increase in 
obese subjects in both diabetics and healthy individuals, but this increase did not reach a significant 
levels. In this age group, in diabetics and healthy individuals, the IGF-1 circulating levels, showed 
no significant differences among different BMIs.   
 
 
KUFA JOURNAL FOR NURSING SCIENCES Vol.4 No. 3 2014 
 
5 
 
Table 2: Difference values of LVM in lean and obese healthy and diabetic subjects  
P value             LVM 
0.04 
 
Lean healthy middle age subjects n=18 
Obese healthy middle age subjects n=17 
0.5 
 
Lean diabetic middle age subjects n=14 
Obese diabetic middle age subjects n=15 
 
Table 2 shows that regarding LVM, There are a significant differences between lean and 
obese healthy middle age individuals (p=0.04), whereas no significant difference between 
lean and obese diabetic subject in the same age group (p=0.5)                                                                 
 
   Table 3: Subjects' profile of echocardiographic data and GH/IGF-1 levels in healthy 
individuals and diabetics of age >60yrs, of different BMIs.n=81                                                 
groups 
 
LVESMS 
dyne/cm 
LVMI 
LVM 
IGF-1ng/ml 
Lean 
Diabetic n=21 44.86±12.36 127.88±69.89 167.7±75.4 20.24±22.10 
Healthy n=15 51.88±9.69 141.33±87.00 179.61±83.61 40.46±6.54 
   P value 0.151 0.943 0.99 0.008** 
Obese 
Diabetic n=16 51.05±23.19 149.84±39.16 129.02±80.01 17.68±5.39 
Healthy n=29 54.20±12.66 167.87±89.62 134.08±112.63 19.68±7.43 
   P value 0.724 0.341 0.50 0.281 
Table 3 shows that  the elderly (>60yrs), in both diabetics and healthy individuals, the 
LVMESS did not show statistical significant variation at different BMIs, in both diabetics and 
healthy subjects. The LVMI did not show statically significant changes in different BMIs in both 
diabetics and healthy individuals. In this group, the GH did not show significant variation between 
diabetics and healthy individuals. The IGF-1 showed significant increase in diabetics, only in lean 
subjects (p < 0.01). No statistical significant changes in IGF-1 observed in obese subjects,.                                                                                                              
Independent sample t-test, ** significant at (P≤0.05) 
 
 
Table 4: difference values of LVM in lean and obese healthy and diabetic subjects.  
 
P value LVM 
0.06 Lean healthy old age subjects n=15 
Obese healthy old age subjects n=29 
0.7             Lean diabetic old  age subjects n=21 
Obese diabetic old  age subjects n=16 
 
Table 4 shows that in both healthy and diabetic individuals there are no significant difference 
in LVM between lean and obese subjects.(p=0.06;0.7 respectively). 
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Figure 1.a correlation of LVESMS with IGF-1in lean diabetics,                         Figure 1.b correlation of LVESMS&IGF-1 in lean healthy, aged aged 
40-60 yrs                                                                                                         40-60 yrs    
                                                                                      
 
 
 
 
 
 
. 
Figure 2.a correlation of LVESMS & IGF-1in lean diabetics                   Figure 2.b correlation of LVESMS&IGF-1 in lean healthy  aged  >60 yrs 
aged >60 yr 
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Figure 4.a  correlation between  LVESMS and IGF-1 in lean diabetics                          Figure 4.b correlation between  LVESMS  and IGF-1 in  aged 
>60   yrs                                                                                                                       lean   healthy,  aged >60yrs                                                               
                                             
In middle age healthy lean individuals (age 40-60 yrs, n=13, BMI<25 kg/m
2
), the mean 
values for LVESMS, IGF-1 plasma levels were 71.74 ± 13.50 dynes /cm
3 
and 38.31±10.65ng/ml, 
respectively. In this group, IGF-1 had no significant correlation with the LVESMS, p value 0.7, r = 
0.08.  In middle- aged obese healthy individuals (age 40-60 yrs, n=16, BMI<25 kg/ m
2
),  the mean 
values for LVESMS and IGF-1 plasma levels were 61.23 ± 20.11dyne/cm 
3
 and 37.58± 30.22 ng/ml 
respectively. No significant correlation was observed between IGF-1 levels and LVESMS, ( p value 
0.37,  r =0.23), as shown in figures 1b and 3b.                                                                                                                                   
  In the elderly lean healthy individuals (age>60 yrs, n=12, BMI>25), the mean values of 
LVESMS; GH, IGF-1 plasma levels were 60.4±14.3dyne/cm 
3
; 1.617 ± 0.88 ng/ml ;49.22±34.980 
ng/ml,  respectively; a negative non-significant correlation was observed between  IGF-1 and 
LV
ESM
S
 
Figure 3.b Correlation between LVESMS and IGF-1 level in obese non 
diabetics aged 40-60yrs. 
 
Figure 3.a Correlation between LVESMS and IGF-1 level in obese 
diabetics aged 40-60 yrs. 
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LVESMS, p =0.23, r=0.37. Whereas In the elderly obese healthy individuals(age>60 yrs, n=20, 
BMI >  ) the mean values of LVESMS; GH, IGF-1 plasma levels were 58.4±14.3dyne/cm 
3
; 1.421 
± 0.78 ng/ml ; 44.22±32.970 ng/ml,  respectively;  a negative significant correlation was observed 
between  IGF-1 and LVESMS, p =0.04,r=0.46, as shown in figures 2a and 4a 
                                                                        
 In middle-aged lean diabetics, (n=15), the mean±S.D values for LVESMS and IGF-1, levels 
were 53.9± 17.8 dynes/cm
3
 and 44.54 ng/ml, respectively. There was no significant correlation 
observed between IGF-1 level and LVESMS, (p=0.95; r=0.01). Whereas, in obese diabetics of age 
40-60yrs, n=17,  the mean±S.D values for for LVESMS and, IGF-1, levels were 53.9± 17.8 
dynes/cm
3 
 and 44.54 ng/ml, respectively There was a negative, but non-significant correlation 
observed between LVESMS and  IGF-1 level (p=0.57, r=0.14),as shown in figures 1a and 3a.                                                                                                         
  In the elderly lean diabetics (n=10), the mean values of LVESMS andIGF-1, levels were 
49.7± 17.8 dynes/cm
3
 and 39.44 ng/ml, respectively. There was a negative non-significant 
correlation observed between LVESMS and IGF-1 level (p=0.07;r=0.58). Whereas in the elderly 
obese diabetics (n=32), the mean values of LVESMS and IGF-1, levels were 48.4± 15.8 dynes/cm 
3
 
0.43 ±1.90 ng/ml and 37.8 ng/ml, respectively; no significant correlation observed between 
LVESMS and  IGF-1 level (p=0.28;r=0.10), as illustrated in figures .a and 4b.                                                                                                                                         
Regarding correlation of LVM with IGF-1, in both middle and old age show no significant 
correlation except in elderly obese diabetic subjects show negative significant correlation 
(p=.0001).                                                                                                                                    
 
DISCUSSION 
In certain progressive metabolic disorders, such as  obesity, and obesity related T2DM, the  
impact of alteration in the circulatory IGF-1 levels, on overall myocardial performance has featured 
the interest of several studies. 
The present results showed  increased LVM in obese individuals with or without diabetes , 
these results are consistent with the previous studies demonstrating both obesity and type 2 diabetes 
could cause abnormalities in cardiac geometry (remodeling)  and function independent of coronary 
artery ischemia and hypertension  (16, 17) .  Hence, according to laplace’s law,  the LVMSS decreased 
in these patient (tables 3 and 4). Our data contradict with study of Postel-Vinay et al.(18) . Their 
conclusion was that increased systolic function measured by increased shortening fraction and 
lower wall stress could occur in obese young adult. The discrepancy of the results may be attributed 
to the differences in the measures used for estimation of  LV systolic function. 
 
In the present study,  age related to  IGF-1 levels  were demonstrated. IGF-1 levels relatively 
increased in middle aged and decreased in the elderly obese individuals. No significant correlations 
were found between IGF-1 and BMI or other indices of adiposity.  These results corroborates with 
the past investigations 
(19)
.  
 
Regarding the proposed link  between LV mass and  free IGF-1 circulating levels, our data  
showed   a multifaceted  interrelationship which  was also in agreement with other researchers. A 
negative correlation between IGF-1 and LVM observed in the lean and obese elderly, with or 
without diabetes. Whereas a positive correlation observed in lean and obese middle aged with or 
without diabetes 
(20)
. Owing to its load independency, we implemented the use LV meridional stress 
as a parameter of LV Afterload measure to reflect LV systolic function taking into account the 
closely inter-related factors that are known to  influence LV systolic function notably, the BMI,  LV 
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ventricular mass and and  GH/IGF-1 axis. Of note, the reported normal IGF-1 plasma levels by 
several investigators are wide raged and conflicting. This inconsistency was attributed to 
differences in age, sex and the degree of obesity 
(20)
.  In an attempt to study the free GH/IGF-1 
levels in middle- aged Korean obese males, Maccaario etal 
(21)
 showed in obese individuals, The 
GH level was reduced, whereas IGF 1 level did not differ significantly. However, the author 
reported that inconsistent results presented by others due to differences in age, sex and the degree of 
obesity.  
In this study, non- linear  relationship existed between IGF-1 levels and LVMSS in  age 
adjusted obese groups. Non significant relationship in the young, significant inverse  relationship in 
the middle aged  diabetics and  negative but non significant association in the elderly healthy obese. 
A wide range of mechanisms involving interactions among several factors. The inconsistency of 
these findings could be explained by the following : 1)  IGF-1 bioactivity is more in young and 
middle aged, a decreased  bioavailabiliy  in the elderly 
(21, 22 )
, 2) GH/IGF-1 deficiency contributes 
to physiological age-related cardiovascular modifications, such as decrease in the number of cardio 
myocytes  
(22)
, 3) a wide range of IGF-1 normal plasma  levels have been reported by considerable 
number of literature, 4) a possible IGF-I /leptin interplay: it has been shown an inverse association 
between leptin and IGF1, 5) in the obese, there could be an interplay between leptin, GH-IGF-1 
axis and insulin resistance. In the obese, it has been shown that GH/IGF-1 axis can be altered at 
different levels, And finally, The GH secretion is  blunted GH secretion may be paired with either 
normal, low or high IGF-1 levels. IGF-binding protein-1 (IGFBP-1) and IGFBP-2 plasma levels are 
blunted due to inhibition by insulin, which is generally increased in obese subjects 
(22, 23).
  
It is pertinent to point out that total IGF-1 concentrations do not necessarily reflect IGF- 1 
activity. Recently, the IGF-1/IGFBP-3 molar ratio has been indicated to reflect the amount of 
unbound and biologically active IGF-1
(23)
. However, a low level in old age may indicate impaired 
LV function, though this notion necessitates large sample studies. 
 
CONCLUSION 
IGF-1 level– LVMESS relationship can be modulated by age, obesity and obesity related 
diabetes. The inverse association of IGF-1 level with LVMESS  in middle aged diabetics and 
elderly healthy obese subjects  may raise the speculation of its utility as a predictor for assessment 
of  LV systolic function. 
 
RECOMMENDATION 
It is suggested that using IGF-1 plasma levels in the elderly with or without T2DM could aid 
as predictor for LV  global systolic dysfunction .However, larger sample size are to be considered. 
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